Milech
Nadia Milech, Perth AU
Patent application number | Description | Published |
---|---|---|
20100190698 | Neuroprotective peptide inhibitors of AP-1 signaling and uses therefor - The present invention provides AP-1 signaling inhibitory peptides comprising the amino acid sequences of SEQ ID NOS: 28-31, 36-39, 45-48, 54-57 and 62-65, compositions comprising one or a plurality of said peptides, and methods of treatment of neurological disorders comprising the administration of the peptide(s) or compositions. | 07-29-2010 |
Nadia Milech, Daglish AU
Patent application number | Description | Published |
---|---|---|
20100166835 | Compositions and uses thereof for the treatment of wounds - The present invention provides a topical composition comprising (i) an amount of an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and/or necrosis induced by dermal wounding and/or to induce and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient e.g., a topical carrier or excipient or other carrier or excipient for dermal application. For example, the AP-1 signaling inhibitor is a peptide analog comprising the sequence set forth in SEQ ID NO: 104. The present invention also provides a method of treating a dermal wound comprising topically administering said topical composition to a subject suffering from a dermal wound. | 07-01-2010 |
Nadia Milech, Western Australia AU
Patent application number | Description | Published |
---|---|---|
20090011405 | Modulating Screening Thresholds for N-Hybrid Screening - The present invention provides improved N-hybrid assays. In particular, the present invention provides an improved reverse N-hybrid assay comprising modulating the amount of a substrate of a reporter gene and/or the amount of a reporter gene thereby enhancing cell death in the absence of a peptide inhibitor of a DNA-protein or protein-protein interaction and/or enhancing cell survival in the presence of a peptide inhibitor of a DNA-protein or protein-protein interaction. Furthermore, the present invention provides an improved forward N-hybrid assay comprising modulating the amount of a reporter gene thereby enhancing cell death in the absence of a heterologous peptide or protein capable of binding to the DNA or protein in a cell and enhancing cell survival in the presence of a heterologous peptide or protein capable of binding to the DNA or protein in a cell. | 01-08-2009 |
Nadia Marian Dorothy Milech, Daglish AU
Patent application number | Description | Published |
---|---|---|
20110053831 | COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND CLINICAL DISORDERS ASSOCIATED WITH THEREWITH - Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS. | 03-03-2011 |
Nadia M. D. Milech, Daglish AU
Patent application number | Description | Published |
---|---|---|
20110218118 | PEPTIDE MODULATORS OF CELLULAR PHENOTYPE AND BI-NUCLEIC ACID FRAGMENT LIBRARY - The present invention provides a non-hybrid screening method for the identification and/or isolation of a peptide that is capable of modulating a phenotype in a cell, tissue or organism. For example, the non-hybrid screening method identifies a peptide that is derived from an organism that is unrelated to the cell, tissue or organism. Alternatively, or in addition, the non-hybrid screening method identifies a peptide that is capable of rescuing the cell, tissue or organism from cell death or inducing a cell, tissue or organism to grow. The present invention also provides a non-hybrid screening method for identifying a peptide that is useful for treating a disease and/or disorder. | 09-08-2011 |